Cargando…

BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?

BRAF inhibitor monotherapy appears to be ineffective in BRAF(V600E)-positive colorectal cancer (CRC) as a result of inherent EGFR-mediated resistance mechanisms. This concept initiated combinatorial treatment approaches. Nevertheless, BRAF inhibition in isogenic CRC cell lines induced enhanced cell-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herr, Ricarda, Brummer, Tilman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905336/ https://www.ncbi.nlm.nih.gov/pubmed/27308494 http://dx.doi.org/10.1080/23723556.2014.1002709

Ejemplares similares

Endosomal acidification inhibitors for the treatment of BRAF mutant tumors
por: Espinosa, Lluís
Publicado: (2015)

BRAF-targeted therapy and immune responses to melanoma
por: Ngiow, Shin Foong, et al.
Publicado: (2013)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells
por: Schilling, Bastian, et al.
Publicado: (2013)

The consensus immunoscore: toward a new classification of colorectal cancer
por: Lanzi, Anastasia, et al.
Publicado: (2020)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

BRAF-targeted therapy alters the functions of intratumoral CD4(+) T cells to inhibit melanoma progression
por: Ho, Ping-Chih, et al.
Publicado: (2014)

Toward a rational design of combination therapy in cancer
por: Doucey, Marie-Agnès, et al.
Publicado: (2015)

A mechanism for the response of KRAS(G13D) expressing colorectal cancers to EGFR inhibitors
por: McFall, Thomas, et al.
Publicado: (2020)

HDAC inhibitors and their potential applications to glioblastoma therapy
por: Adamopoulou, Eleni, et al.
Publicado: (2013)

Fateful music from a talented orchestra with a wicked conductor: Connection between oncogenic BRAF, ER stress, and autophagy in human melanoma
por: Giglio, Paola, et al.
Publicado: (2015)

The colorectal cancer immune paradox revisited
por: Angelova, Mihaela, et al.
Publicado: (2015)

Macrophages: Good guys in colorectal cancer
por: Edin, Sofia, et al.
Publicado: (2013)

Differentiation therapy for glioblastoma – too many obstacles?
por: Carén, Helena, et al.
Publicado: (2015)

Addressing a weakness of anticancer therapy with mitosis inhibitors: Mitotic slippage
por: Balachandran, Riju S., et al.
Publicado: (2017)

Personalized peptide vaccination for advanced colorectal cancer
por: Sasada, Tetsuro, et al.
Publicado: (2015)

Hunting for clues: Regulatory T cells and colorectal cancer
por: Gallimore, Awen, et al.
Publicado: (2012)

LPCAT2 controls chemoresistance in colorectal cancer
por: Cotte, Alexia Karen, et al.
Publicado: (2018)

Multiverse of immune microenvironment in metastatic colorectal cancer
por: Van den Eynde, Marc, et al.
Publicado: (2020)

BRCA1: a movement toward cancer prevention
por: Alli, Elizabeth, et al.
Publicado: (2015)

Discovery and validation of the antimetastatic activity of citalopram in colorectal cancer
por: Iskar, Murat, et al.
Publicado: (2015)

Toll-like receptor genetic variants and colorectal cancer
por: Weber, Alexander NR, et al.
Publicado: (2014)

Toward understanding the genetics of regulatory T cells in ovarian cancer
por: DeRycke, Melissa S, et al.
Publicado: (2013)

DDR1 inhibition as a new therapeutic strategy for colorectal cancer
por: Sirvent, Audrey, et al.
Publicado: (2018)

The role of FOXP3 in disease progression in colorectal cancer patients
por: Grimmig, Tanja, et al.
Publicado: (2013)

Stromal CEACAM1 expression regulates colorectal cancer metastasis
por: Arabzadeh, Azadeh, et al.
Publicado: (2012)

Targeting copper metabolism to defeat KRAS-driven colorectal cancer
por: Aubert, Léo, et al.
Publicado: (2020)

Combining forces to hit cancer stem cells: TRAIL-lymphocytes and EpCAMxCD3 bispecific antibody show efficacy against pancreatic cancer
por: Herr, Ingrid, et al.
Publicado: (2012)

Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies
por: Omokoko, Tana, et al.
Publicado: (2015)

Interleukin 21 impairs tumor immunosurveillance of colitis-associated colorectal cancer
por: Kesselring, Rebecca, et al.
Publicado: (2012)

Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
por: Thibaudin, Marion, et al.
Publicado: (2023)

Toward the next generation of NK cell-based adoptive cancer immunotherapy
por: Ni, Jing, et al.
Publicado: (2013)

Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment
por: Michielsen, Adriana J., et al.
Publicado: (2012)

Itraconazole perturbs colorectal cancer dormancy through SUFU-mediated WNT inhibition
por: Popova, Semiramis A., et al.
Publicado: (2018)

Tumor conditioned media from colorectal cancer patients inhibits dendritic cell maturation
por: Michielsen, Adriana J., et al.
Publicado: (2012)

Cancer testis antigens: A new paradigm for cancer therapy
por: Suri, Anil, et al.
Publicado: (2012)

PNP inhibitors selectively kill cancer cells lacking SAMHD1
por: Davenne, Tamara, et al.
Publicado: (2020)

Regulation of cancer stem-like cell differentiation by Smac mimetics
por: Fulda, Simone
Publicado: (2014)

HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates
por: Schulz, Ramona, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_n69s7k1m360incnf7aj36o99rg